303 related articles for article (PubMed ID: 24811161)
1. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.
Buchner M; Müschen M
Curr Opin Hematol; 2014 Jul; 21(4):341-9. PubMed ID: 24811161
[TBL] [Abstract][Full Text] [Related]
2. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
3. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.
Puri KD; Di Paolo JA; Gold MR
Int Rev Immunol; 2013 Aug; 32(4):397-427. PubMed ID: 23886342
[TBL] [Abstract][Full Text] [Related]
4. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Koehrer S; Burger JA
Clin Adv Hematol Oncol; 2016 Jan; 14(1):55-65. PubMed ID: 27057669
[TBL] [Abstract][Full Text] [Related]
5. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.
Rickert RC
Nat Rev Immunol; 2013 Aug; 13(8):578-91. PubMed ID: 23883968
[TBL] [Abstract][Full Text] [Related]
6. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.
Gobessi S; Laurenti L; Longo PG; Sica S; Leone G; Efremov DG
Blood; 2007 Mar; 109(5):2032-9. PubMed ID: 17038529
[TBL] [Abstract][Full Text] [Related]
7. VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects.
Härzschel A; Zucchetto A; Gattei V; Hartmann TN
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32210016
[TBL] [Abstract][Full Text] [Related]
8. B cell receptor signaling in chronic lymphocytic leukemia.
Burger JA; Chiorazzi N
Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
[TBL] [Abstract][Full Text] [Related]
9. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Wang Y; Zhang LL; Champlin RE; Wang ML
Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
[TBL] [Abstract][Full Text] [Related]
10. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
[TBL] [Abstract][Full Text] [Related]
11. B-cell receptor signaling as a driver of lymphoma development and evolution.
Niemann CU; Wiestner A
Semin Cancer Biol; 2013 Dec; 23(6):410-21. PubMed ID: 24060900
[TBL] [Abstract][Full Text] [Related]
12. Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.
Waibel M; Gregory G; Shortt J; Johnstone RW
Curr Opin Hematol; 2014 Jul; 21(4):297-308. PubMed ID: 24811162
[TBL] [Abstract][Full Text] [Related]
13. Atypical B cell receptor signaling: straddling immune diseases and cancer.
Faris M
Int Rev Immunol; 2013 Aug; 32(4):355-7. PubMed ID: 23848467
[TBL] [Abstract][Full Text] [Related]
14. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
Ten Hacken E; Gounari M; Ghia P; Burger JA
Leukemia; 2019 Feb; 33(2):287-298. PubMed ID: 30555163
[TBL] [Abstract][Full Text] [Related]
15. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
16. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Valla K; Flowers CR; Koff JL
Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
[TBL] [Abstract][Full Text] [Related]
17. Stereotyped B cell receptors in B cell leukemias and lymphomas.
Darzentas N; Stamatopoulos K
Methods Mol Biol; 2013; 971():135-48. PubMed ID: 23296962
[TBL] [Abstract][Full Text] [Related]
18. Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.
Patton JT; Woyach JA
Semin Hematol; 2024 Apr; 61(2):100-108. PubMed ID: 38749798
[TBL] [Abstract][Full Text] [Related]
19. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
Köhrer S; Havranek O; Seyfried F; Hurtz C; Coffey GP; Kim E; Ten Hacken E; Jäger U; Vanura K; O'Brien S; Thomas DA; Kantarjian H; Ghosh D; Wang Z; Zhang M; Ma W; Jumaa H; Debatin KM; Müschen M; Meyer LH; Davis RE; Burger JA
Leukemia; 2016 Jun; 30(6):1246-54. PubMed ID: 26847027
[TBL] [Abstract][Full Text] [Related]
20. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
